Novaliq Gmbh

Lonza Inc.

Lts Lohmann Therapie-systeme Ag

Dermaliq Therapeutics, Inc.

Lonza Guangzhou Pharmaceutical Ltd.

Dieter Scherer

Bernhard Günther

Bastian Theisinger

Sonja Theisinger

Anthony Pettigrew

Frank Löscher

Ralf Grillenberger

Hartmut Voss

Clive G Wilson

Gesche Graf

Annette Hüttig

Paul Hanselmann

Sandra Wiedersberg

Yanling Yang

Daniel Shan

Reta Zhu

Jieping Wei

Heping Xu

Annette Huttig

Berhard Gunther

Clive Wilson

Annette HÜTTIG

The invention relates to the use of semi-fluorinated alkanes, in particular mixed with ethanol, as solubilising agents, permeation promoters and/or enhancers for lipophilic and/or poorly skin-permeable pharmaceutical agents that are administered via a transdermal therapeutic system (TTS), and to corresponding TTSs containing such substances.

Use of semi-fluorinated alkanes in transdermal therapeutic systems

The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

Semifluorinated compounds and their compositions

The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

Compositions comprising mixtures of semifluorinated alkanes

The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.

Stabilized antibody compositions

The invention provides novel compositions of bioactive polypeptides and proteins with improved stability and shelf-life. The compositions are based on liquid vehicles selected from semifluorinated alkanes. These vehicles are remarkably effective in protecting polypeptides and proteins from degradation and/or aggregation. The compositions are useful for topical administration, e.g. into an eye, or by parenteral injection, e.g. via the subcutaneous or intramuscular route.

Stabilised protein compositions based on semifluorinated alkanes

The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.

Topical pharmaceutical composition based on semifluorinated alkanes

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

Semifluorinated alkane compositions

The invention discloses a method for preparation of 1,4-sorbitan by dehydration of D-sorbitol, wherein one equivalent of water is removed and a cyclization occurs, followed by a treatment with ethanol and isopropanol.

Method for preparation of 1,4-sorbitan

The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

Semifluorinated compounds

Methods of treating ocular disorders using semifluorinated alkanes

Growing community of inventors

Laufen, Switzerland

Dieter Scherer